TIKUN Europe: Invests 40 million in Greece for the production of medicinal cannabis preparations.

TIKUN Europe is proceeding with the creation of the largest unit for the production of medical cannabis preparations in Europe, investing a total of 40 million euros in a privately owned area of ​​56,000 sq.m. At Corinth. The opening of the factory is expected to have multiple benefits for the economy, trade, local community and patients and consumers in Greece and throughout Europe. The focus of the business is to create a positive footprint for the economic development and prosperity of the local community, placed in a field of business activity with a wide range and value of several billion worldwide. This investment is estimated to create 130 new jobs in the region.

From the R&D department of Greece the development of the TIKUN CBD series in 2022

The production facility will be fully vertical, with a Research and Development department and state-of-the-art equipment. In fact, the role of the R&D department will be decisive, given that from 2022 the pharmaceutical company will place on the European market the TIKUN CBD product line, which will be developed by the Research and Development department of Greece, while its production will be implemented. in a certified factory in France. The TIKUN CBD series has a benefit for the human body as a whole and at the same time acts purposefully on the annoyances of everyday life, offering a holistic approach and natural balance, while ensuring homeostasis.

TIKUN Europe is the first pharmaceutical company active in the field of medical cannabis in Greece, having in its assets a wide scientific heritage, know-how, international course and the Tikun Olam awards.

The Vision “Repair the World”

The brand name TIKUN was created by the Israeli company TIKUN OLAM, in 2005. The company’s vision is summarized in the interpretation of the name “Repair the World”. It is the Company that since 2005 essentially defines the market of medical cannabis worldwide, leading the way in the research, development and production of products of the category.

Its aim and main goal is to continuously improve and upgrade the quality of life of patients and consumers. It has more than 15 years of clinical and laboratory studies as well as an extensive database, with data from at least 30,000 patients, which is constantly enriched. Its productive model includes the production of pharmaceuticals with an innovative footprint, based on internationally awarded cannabis strains.

TIKUN factories currently operate in the United States and Canada, Australia, Israel and Europe, with headquarters in Greece.

Mission of TIKUN Europe to have products that come from nature and are based on science

The medicines developed by Tikun Europe are based on molecules of plant origin and are the result of thorough scientific research. The Company’s mission is to market products that “come from nature and are based on science”, with the central message “Made by Nature Backed by Science”. ).

The action of TIKUN Europe drugs can offer support in diseases such as Parkinson’s disease, Crohn’s disease, Autism, Multiple Sclerosis and Epilepsy. They also contribute to the treatment of neuropathic pain, the side effects of chemotherapy, as well as the treatment of diseases related to key areas of overall health and functioning of the human body.

The core values ​​of the company include integrity and transparency, passion for research and development as well as innovation, faith in the person and patient support. The basic belief of TIKUN and its executives is that every person and patient is unique. That is why it gives special importance to the development of its teams and partners, so that both they and the company are useful to society as a whole.